Mature MAO-B reference standard with solid clinical evidence but limited frontier research appeal
Rasagiline is the second-generation irreversible MAO-B inhibitor that largely displaced selegiline’s role in Parkinson pharmacology by doing one thing better: it doesn’t metabolize to amphetamines. That’s a meaningful difference in practice. Teva’s development team got this right, and the FDA agreed in 2006. The PRESTO, TEMPO, and LARGO trials gave it solid regulatory legs across both monotherapy and levodopa-adjunct settings.
The more interesting research angle isnt the MAO-B inhibition itself, which is textbook at this point, but the propargylamine-mediated neuroprotection signal that sits underneath it. The propargyl group appears to influence Bcl-2 family expression, APP processing, and mitochondrial membrane stability through mechanisms that are partly independent of MAO-B. The ADAGIO delayed-start trial tried to pin this down. At 1 mg, it showed a weak disease-modification signal; at 2 mg, it didn’t, which muddied the interpretation. The FDA reviewed this carefully and declined a neuroprotection label claim, but the biological question isnt fully closed, and several groups have continued probing propargylamine biology in cell and rodent models. Thats where the remaining bench interest lives.
Here’s the thing though: rasagiline isnt on the frontier anymore. Safinamide arrived as a reversible, selective MAO-B inhibitor with an additional sodium-channel and glutamate-release angle that gives it a more interesting pharmacological story for combination PD research. The longevity-oriented MAO-B work has largely migrated toward broader monoamine biology in the context of aging rather than Parkinson’s specifically, and rasagiline doesn’t have the novel positioning to anchor that conversation the way a mitochondrial-targeted peptide or an mTOR-adjacent compound might. Its 14:1 MAO-B selectivity is good; it’s just not surprising anymore.
We think rasagiline earns its place in a research library as a reference standard rather than a frontier target. If your program involves dopamine metabolism, MAO-B selectivity profiling, or the propargylamine neuroprotection hypothesis, it’s a clean, well-sourced, thoroughly characterized tool. The irreversible kinetics are well-documented; the approximately 14-day recovery period is practically useful for experimental design. It’s just not a compound where bench work is likely to surface surprising findings in 2026. The primary questions have been asked, the big trials are done, and the remaining uncertainty around neuroprotection is real but not easily resolved at bench scale. Solid compound. Not an exciting one.